The Ministry of Health of the Nation reported this Wednesday that during the last 24 hours 145 deaths and 11,765 new positive cases of COVID-19 were registered. With these data, the total number of infected amounts to 1,613,928 and the fatalities total 43,163.
Of the total deaths, 80 are men (13 from the province of Buenos Aires, seven from the city of Buenos Aires, one from Chaco, two from Córdoba, two from Corrientes, one from Entre Ríos, one from Mendoza, 17 from Neuquén, four from Río Negro, one from Santa Cruz, 17 from Santa Fe, three from Tierra del Fuego and 11 from Tucumán) and 65 women (23 from the province of Buenos Aires, eight from the city of Buenos Aires, five from Chaco, one from Córdoba, four from Corrientes, three from Entre Ríos, one from Mendoza, six from Neuquén, three from Río Negro, one from Salta , eight from Santa Fe and two from Tucumán).
In the last 24 hours, 54,126 tests were carried out and since the beginning of the outbreak, 4,811,498 diagnostic tests were carried out for this disease, which is equivalent to 106,034 samples per million inhabitants.
Currently there are 3,340 people admitted to Intensive Care Units (ICU). With regard to occupancy percentages, at the national level it is 53.3%, while in the AMBA it is 57%.
Of the 11,765 new infections, 4,761 from the province of Buenos Aires, 1,076 from the city of Buenos Aires, 62 from Catamarca, 249 from Chaco, 538 from Chubut, 118 from Corrientes, 763 from Córdoba, 419 from Entre Ríos, 22 from Jujuy , 321 from La Pampa, 10 from La Rioja, 169 from Mendoza, 32 from Misiones, 518 from Neuquén, 387 from Río Negro, 52 from Salta, 148 from San Juan, 38 from San Luis, 434 from Santa Cruz, 1,307 from Santa Fe, 123 from Santiago del Estero, 67 from Tierra del Fuego and 151 from Tucumán.
This Wednesday morning the vaccination against the coronavirus with the Russian Sputnik V vaccine continued. On the second consecutive day of inoculation, health professionals received the dose.
On the other hand, National Administration of Medicines, Food and Medical Technology (ANMAT) authorized this Wednesday under the emergency registration modality the vaccine against the SARS-CoV-2 virus developed by the University of Oxford and the company AstraZeneca SA
“The application for registration submitted by the owner of the product is framed within the provisions of Annex I- Item 5 of the ANMAT Provision 705/05, which provides for the registration of vaccines of health interest in emergencies”, they indicated.
In the report they explained that “the product presents an acceptable benefit-risk balance, allowing to support the granting of the registration and conditional authorization of the product for the requested indication.”
And they added that “It was granted for a period of one year from the date of this provision, under the condition of sale under prescription.”
“The Risk Management Plan (PGR) established to closely monitor the safety and efficacy of the drug must be complied with and the corresponding progress reports, modifications and updates must be submitted to the National Institute of Medicines (INAME)”, concluded from ANMAT.
The Argentine government and AstraZeneca signed an agreement for more than 22 million doses of the vaccine that would be available in the country as of March, and at present said active substance is being produced in the country.
I kept reading:
ANMAT approved the emergency use of the Oxford-AstraZeneca vaccine in Argentina
The advantages of the Oxford vaccine that could change the course of the pandemic in the region